SlidesetHIVINTEREST 2017Universal access to all essential medicines – What can be done?- Andrew Hill, MDView Slideset
SlidesetHIVINTEREST 2017Progress in HIV prevention and treatment scale-up in sub-Saharan Africa- Karim AkadiriView Slideset
SlidesetHIVINTEREST 2017ART rapid scale-up: The implications for patient care and retention- Francesca Conradie, MBChB (Wits), DTM&HView Slideset
PCPep CollMD, MSSlidesetHIVSpanish HIV Clinical Forum 2017PrEP and prevention- Pep Coll, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. MurView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-TorresView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. MontejanoView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Dolutegravir and lamivudine as dual maintenance therapy- R. MontejanoView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. SantosView Slideset
CBCharles BoucherMD, PhDSlidesetHIVSpanish HIV Clinical Forum 2017HIV Prevention 2.0- Charles Boucher, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MDView Slideset
